Eisenberger Claus F, Knoefel Wolfram T, Peiper Matthias, Merkert Petra, Yekebas Emre F, Scheunemann Peter, Steffani Katharina, Stoecklein Nikolas H, Hosch Stefan B, Izbicki Jakob R
Department of General Surgery, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
Clin Cancer Res. 2003 Sep 15;9(11):4178-83.
Esophageal squamous cell cancer can be treated effectively by potentially curative surgery if diagnosed at an early stage. Our aim was to develop a novel molecular approach as a noninvasive test for squamous cell cancer detection and as an indicator for the prognosis of the patients.
Matched normal, tumor, and serum samples were obtained from 28 patients with squamous cell carcinoma (SCC) of the esophagus. DNA was extracted, and the samples were subjected to microsatellite analysis using 12 markers. Serum and normal DNA from 10 healthy individuals served as controls.
Twenty-six of the 28 patients (92.9%) with SCC were found to have one or more microsatellite DNA alterations in their primary tumor. Twenty-seven of the 28 patients (96.4%) had at least one alteration in the serum by microsatellite analysis. Mean age was 61.5 years. Microsatellite alterations were not identified in the serum DNA of samples from normal control subjects. Median follow-up was 13 months. Survival and recurrence were not significantly correlated with either loss of heterozygosity in the tumor or in the serum.
Microsatellite DNA analysis of tumor and serum specimen is a potentially valuable tool for detection and for the evaluation of the prognosis of SCC of the esophagus. The follow-up in our study is still too short to draw final conclusions on the correlation of disease-specific survival and disease recurrence with microsatellite alterations. The evidence of circulating tumor DNA in almost all of our patients underlines a systemic component of the disease that is not surgically amenable.
如果能早期诊断，食管鳞状细胞癌可通过潜在的根治性手术得到有效治疗。我们的目标是开发一种新的分子方法，作为鳞状细胞癌检测的非侵入性检测手段以及患者预后的指标。
从28例食管鳞状细胞癌（SCC）患者中获取匹配的正常、肿瘤和血清样本。提取DNA，并使用12个标记对样本进行微卫星分析。来自10名健康个体的血清和正常DNA作为对照。
28例SCC患者中有26例（92.9%）在其原发肿瘤中发现有一个或多个微卫星DNA改变。通过微卫星分析，28例患者中有27例（96.4%）血清中至少有一个改变。平均年龄为61.5岁。在正常对照受试者样本的血清DNA中未发现微卫星改变。中位随访时间为13个月。生存和复发与肿瘤或血清中的杂合性缺失均无显著相关性。
肿瘤和血清标本的微卫星DNA分析是检测食管SCC及评估其预后的一种潜在有价值的工具。我们研究中的随访时间仍然太短，无法就疾病特异性生存和疾病复发与微卫星改变的相关性得出最终结论。几乎所有患者中循环肿瘤DNA的证据强调了该疾病的系统性成分，这是手术无法解决的。
